0000899243-20-022431.txt : 20200814
0000899243-20-022431.hdr.sgml : 20200814
20200814165338
ACCESSION NUMBER: 0000899243-20-022431
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200812
FILED AS OF DATE: 20200814
DATE AS OF CHANGE: 20200814
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Akinsanya Karen
CENTRAL INDEX KEY: 0001797672
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39206
FILM NUMBER: 201106231
MAIL ADDRESS:
STREET 1: SCHRODINGER, INC.
STREET 2: 120 WEST 45TH STREET, 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Schrodinger, Inc.
CENTRAL INDEX KEY: 0001490978
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 954284541
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 503-299-1150
MAIL ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-12
0
0001490978
Schrodinger, Inc.
SDGR
0001797672
Akinsanya Karen
C/O SCHRODINGER, INC.,
120 WEST 45TH STREET, 17TH FLOOR
NEW YORK
NY
10036
0
1
0
0
See Remarks
Common Stock
2020-08-12
4
M
0
13377
3.22
A
13377
D
Common Stock
2020-08-12
4
M
0
3344
2.92
A
16721
D
Common Stock
2020-08-12
4
M
0
3344
2.92
A
20065
D
Common Stock
2020-08-12
4
S
0
200
65.085
D
19865
D
Common Stock
2020-08-12
4
S
0
2697
66.5257
D
17168
D
Common Stock
2020-08-12
4
S
0
7839
67.3469
D
9329
D
Common Stock
2020-08-12
4
S
0
2641
68.1807
D
6688
D
Common Stock
2020-08-12
4
S
0
100
65.05
D
6588
D
Common Stock
2020-08-12
4
S
0
947
66.7291
D
5641
D
Common Stock
2020-08-12
4
S
0
1972
67.557
D
3669
D
Common Stock
2020-08-12
4
S
0
325
68.4108
D
3344
D
Common Stock
2020-08-12
4
S
0
1076
66.6616
D
2268
D
Common Stock
2020-08-12
4
S
0
1861
67.5272
D
407
D
Common Stock
2020-08-12
4
S
0
407
68.1725
D
0
D
Stock Option (right to buy)
3.22
2020-08-12
4
M
0
13377
0.00
D
2028-08-03
Common Stock
13377
40132
D
Stock Option (right to buy)
2.92
2020-08-12
4
M
0
3344
0.00
D
2027-10-10
Common Stock
3344
10033
D
Stock Option (right to buy)
2.92
2020-08-12
4
M
0
3344
0.00
D
2027-10-10
Common Stock
3344
6689
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.77 to $65.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.80 to $66.78, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.80 to $67.79, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.80 to $68.76, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.12 to $67.02, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.15 to $68.11, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.31 to $68.58, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.97 to $66.94, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.02 to $67.94, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.03 to $68.31, inclusive.
The option was granted on August 3, 2018. The shares underlying the option are scheduled to vest in equal yearly installments from May 14, 2018 through May 14, 2022.
The option was granted on October 10, 2017. The shares underlying the option are scheduled to vest in equal yearly installments from August 15, 2017 through August 15, 2021.
Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D
/s/ Yvonne Tran, as attorney-in-fact for Karen Akinsanya
2020-08-14